Posts

7 days in healthcare (October 30th-November 5th, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, the FDA opens the door to the first treatment with CRIPSR gene editing, applied in this case to sickle cell anemia. The “liquid biopsy” seems to be able to detect cancer recurrence before any radiological signs. A change is proposed in the regulation of embryo research. The laws and conventions in force do not allow embryos to be investigated in the laboratory beyond day 14. There is a gap until day 28, when embryos from abortions can already be investigated. This seems to prevent us from knowing many elements of organ development and that is what we are trying to modify. Although it is often assumed that dementia is increasing as the population ages, there appears to already be some evidence that the incidence of dementia is decreasing quite significantly.

As far as Global Health is concerned, the director general of the WHO is alarmed by the indescribable situation in Gaza. Nigeria is preparing to vaccinate 8 million girls with the papillomatosis vaccine, related to cervical cancer.

Regarding International Health Policy, in the United States, despite the prohibition of abortion in some states as a consequence of the Dobbs ruling of the Supreme Court, the abortion rate has not decreased a year after this ruling. The Economist considers how it is possible that doctors in the United States earn so much ($350,000/year on average), coming to the conclusion that it is due to an artificial shortage of doctors, due to the few places in Medical Schools, despite that there is no shortage of candidates. In the United Kingdom, the investigation into covid seems to show the disaster in management during the Boris Johnson period. Bad business, although the case of Spain is worse, where, despite promises, no report on the management of the pandemic has been made public. Health changes are on the horizon in Poland, following the arrival of the new government. Kenya, with 53 million inhabitants, joins the movement of so many other countries to move towards universal health coverage.

If we talk about National Health Policy (Spain), the XENOMA project in Galicia is very important, which aims to analyze the DNA of 400,000 Galicians. One of the precedents is the project to analyze the genome of 100,000 Britons, promoted during the David Cameron period and managed by Genomics England. Surely a project of this style should have been promoted at the national level, but it is good that, in the absence of the above, it should be promoted by an autonomous community. Doubts among experts about one of the measures of the PSOE-Sumar agreement on a law to end waiting lists. Without funding, better accounting and prioritization, organizational measures, new incentives and public/private collaboration, no law is capable of solving this problem. After all, a Royal Decree that establishes maximum times for certain procedures has already been in force since 2011, but it is not being complied with. Virtually all autonomous communities are approving increased health budgets for 2024, rising especially in Primary Care. Just because the budgets grow compared to the previous year does not mean that they are higher than the real spending in 2023, which is happening in Madrid, for example. The PSOE-ERC agreement contemplates the transfer of at least 150 million euros/year to Catalonia, for scientific and technical research.

In the field of Companies, on an international level, Google intends to grow in healthcare, based above all on artificial intelligence tools. Regarding the covid vaccine, GSK raises profit forecasts, while Moderna and Pfizer contemplate setbacks. At the national level, Fresenius sells its Quirón business in Peru. The Sant Joan de Deu Hospital in Barcelona creates an artificial intelligence laboratory with Microsoft.

Biomedicine

Global Health

International health policy

National health policy

Companies

 

 

 

 

7 days in healthcare (September 25th-October 1st, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, The Economist raises the issue of how research on aging makes the prospect of living to 120 years less unimaginable.

Regarding Global Health, The Lancet publishes a study prepared with information from 185 countries that shows how a more “feminist” approach could have saved hundreds of lives of women with cancer. Surprising news from COVAX, the body created to distribute covid vaccines to developing countries: billions of its budget unspent.

Regarding International Health Policy, the pharmaceutical industry warns against the possible harms of the application of the European Union’s pharmaceutical policy, in this case the reduction of medicines against rare diseases. The pharmaceutical policy has not yet been approved, so this sounds like putting the bandage before the wound.

If we talk about National Health Policy (Spain), the news of the week was the failed investiture of Feijóo. In his speech he addressed health problems. Although logically in a discourse of this type the sectoral details must necessarily be brief and what is interesting is the general tone, the poverty of the health discourse is surprising. The proposals are reduced to a shock plan for Primary Care and new medical calls, in addition to a “commission of experts” to address the problems of the sector for which no initial proposal is launched. It does not seem that there is a mature reform program in the PP when it comes to health. The news of the approval of a catalog of biomarkers in the SNS, which will be published electronically, seems like good news.

In the field of Companies, at the international level, the EU’s talks with Moderna for the new supply of covid vaccines should be highlighted. At the national level, Sanitas is reinforced in Andalusia with a new center in Malaga; an Austrian company will create a wellness center in Marbella; and, Atrys Health continues its expansion in Mexico, through an agreement with BUPA.

Biomedicine

Global Health

International health policy

National health policy

Companies

 

7 days in healthcare (August 28th-September 3rd, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, it is worth highlighting how therapy with psychedelics is opening up among mental health professionals, especially for cases of depression, anxiety, post-traumatic stress, eating disorders and addictions.

As far as Global Health is concerned, a study of 18 clinical trials shows that screening for early detection of cancer does not make this population live longer than those who do not undergo this type of testing. WHO concern about blindness and vision disorders. More than 2.2 billion people globally have vision disorders, generally attributable to refractory disorders and cataracts.

In terms of International Health Policy, the expected bomb exploded from the application of the “Inflation Reduction Law”, approved in the USA in August 2022, which included something prohibited until now: price negotiation between pharmaceutical companies and Medicare. . The American government made public the 10 drugs that will be negotiated in 2023 and affects the main companies: Pfizer, Lilly, Novartis, AstraZeneca, J&J, etc. Although the established system is very gradual, since 10 drugs will be negotiated each year for the next four, the truth is that this breaks the status quo of the pharmaceutical industry not only in the USA (the largest drug market) but in the world. It is difficult to counter Biden’s argument, which he plans to use in the 2024 campaign, that Americans do not have to pay two to three times more for medicines than the rest of the developed countries, such as in Europe. However, The Economist, which recognizes the need for this price negotiation, nevertheless sees problems in its application due to the appeals filed by large pharmaceutical companies and the risk that these companies will distance themselves from the necessary medicines and concentrate on others unrelated to price control. He also says that if R&D expenses are taken into account, the profitability of pharmaceutical companies is not extraordinary, when compared to the companies in the S&P 500.

If we talk about National Health Policy (Spain), the incidence of covid shoots up by 70% in just one week. The Ministry of Health recommends the fifth dose to selected groups: over 60 years of age, health personnel and the vulnerable. The Supreme Court faces a complex issue: the ruling on thousands of compensation payments to businessmen due to the pandemic. These are property claims to the State due to Covid-19 from businessmen and self-employed workers, who are awaiting compensation for the damage caused by the restrictions during the states of alarm that were later cancelled.

In the field of Companies, on an international level, the most notable is the abandonment of CENTENE from the United Kingdom, where it had a chain of primary care centers and the CIRCLE hospital network. The movement follows his departure from Spain with the sale of Ribera. A concentration in the American market, difficulties with the anti-privatisation movements of healthcare in Europe and problems with hospital integration may be at the origin of the problems, to which perhaps we should also add an underdeveloped growth strategy for this American company in Europe. In any case, a shame, since CENTENE is a great American insurance company, with a lot to teach in the European world. As far as national news is concerned, Spain is the only country that has purchased (31 million euros) several million vaccines from HIPRA, which is not updated for the new strains. Big problem for the Ministry if it decides to use it.

Biomedicine

Global Health

International health policy

  • USA
    • The American government reveals the 10 drugs on which price negotiations will take place with Medicare. Under the proposed reform the minimum price decrease will be 25%. According to the Congressional Budget Office, the savings to the public coffers will be $100 billion over a decade. The affected companies are BMS, Pfizer, Boeheringer, Lilly, J&J, Merck, AstraZeneca, Novartis, Amgen, AbbVie, Novonordisk (https://www.ft.com/content/fa9b0422-6f93-4703-9358-6396660f63b6)
    • The Economist, critical of the American government’s measure, although it recognizes that price negotiation was obligatory. He says that the prohibition on negotiation was nonsense, but the proposed negotiation system could have perverse effects. If R&D expenses are taken into account, pharmaceutical companies do not have extraordinary profits, compared to those of the S&P 500 (https://www.ecocom/leaders/2023/08/30/americas-new-drug-pricing-rules-have-perverse-consequences)
    • Biden makes the negotiation of drug prices one of the central axes of his campaign for 2024, despite the fact that the price reduction will not begin until 2026 and that is if the law resists all judicial attacks (https://www.nytimes.com/2023/08/30/us/politics/biden-medicare-drug-prices-2024-campaign.html)
    • Opinion article in FT: “The world needs to stop depending on the American pharmaceutical industry.” Americans pay up to three times more than other developed countries for medications. The American market is the main market for pharmaceutical companies. This policy is popular among Americans, but it may affect drug R&D globally. Pharmaceutical companies can orient themselves from the most needed medicines to those that escape price control (https://www.ft.com/content/0c20c518-60a8-4dd0-87be-f03adc8ec0e1)

National health policy

  • Judicial consequences of the pandemic
    • The Supreme Court faces the sentencing of thousands of compensations to businessmen due to the pandemic. These are property claims to the State due to Covid-19 from businessmen and self-employed workers, who are awaiting compensation for the damage caused by the restrictions during the states of alarm that were later cancelled. About 9,000 resources are expected. The sentence is very complex, due, among other things, to the high economic amount that it could represent (https://www.expansion.com/juridico/sentencias/2023/09/01/64f1cc47e5fdea09658b45ba.html)

Companies

 

 

 

7 days in healthcare (July 24th-30th, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, the mRNA vaccine for cancer and regenerative medicine seem to be the great promises in medical advances.

As regards Global Health, The Lancet dedicates an editorial to the need for a broader vision of women’s health, beyond maternal health. The most prevalent disease problems in women are the same as in men, but need insight into specific, poorly understood risks.

As for International Health Policy, the battle continues in the United States for the application of the new pharmaceutical policy that allows Medicare to negotiate the price of drugs, something that until now had been banned. This negotiation will begin in 2024 and it is expected that on September 1, 2023 the medicines on which it will be negotiated will be known. In a movement that seems to be ahead of events, several pharmaceutical companies (Janssen, Merck, Astellas Pharma and BMS) file a lawsuit against the American government. Apart from other possible considerations, it seems difficult to maintain that the price of medicines is much higher in the United States than in other countries, and not only in developing countries, but also in Europe. In the United Kingdom, the British Medical Journal focuses on the financing of pharmaceutical and medical technology companies to British scientific societies. For this, more transparency is required.

If we talk about National Health Policy (Spain), the political changes derived from the regional elections establish a new configuration of the Interterritorial Council, which will be numerically dominated by the PP (which will count, including the Canary Islands Coalition) 12 seats in the Council, by 3 of the PSOE (Castilla-La Mancha, Navarra, Asturias), 1 from the PNV (Basque Country) and 1 from ERC (Catalonia). The Radar Healthcare organization publishes a new ranking of healthcare systems and awards Spain a very favorable position in terms of quality. In general, these types of rankings must be looked at with a magnifying glass and consider the type of indicators analyzed and another series of circumstances. A biased and unprofessional interpretation of the international rankings on the Spanish health system has meant, in practice, a brake on the reforms. If we are so well, why reform anything? It is known that Spain is one of the OECD countries that devotes less public funding to dental care. What we did not know and what is now clear is that it has even dropped very significantly in the last decade, going from 5,245 million euros in 2010 to 3,681 in 2020. It seems clear that Spain, which globally has organized vaccination against covid very well However, it has failed to develop a vaccine: the HIPRA vaccine was delayed much longer than expected and the announced intranasal vaccine no longer even has a release date. It is difficult to compete with vaccines that appear less than a year after the onset of the disease, as has happened in the case of covid, with long development of vaccines that take years.

In the field of Companies, internationally, the president of Novartis (company of European origin) says that the price reform in the United States of medicines represents a threat to Public Health. At the national level, it is worth noting that spending on biosimilars has exceeded 1 billion euros in 2022, due to the fact that the patent for several biological drug molecules has expired and biosimilars have appeared.

Biomedicine

Global Health

International Health Policy

National health policy

  • Changes in the Interterritorial Council
    • Changes in the political sign of the autonomous communities completely modify the political weights in the Interterritorial Council. The popular ones will have 12 seats (with the Canary Islands Coalition), compared to 3 for the socialists (Castilla-La Mancha, Navarra and Asturias), 1 for the PNV (Basque Country) and 1 ERC (Catalonia) (https://gacetamedica.com/opinion/a-new-territorial-council-of-the-sns/)

Companies

7 days in healthcare (July 17th-23rd, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, important editorial and several articles in The Economist on the problems of reproduction and in vitro fertilization. Since this technique began, 45 years ago, more than 12 million children have been born thanks to it. The issue is extremely important considering that one in six people suffer from infertility. IVF is experiencing an extraordinary “boom”. Important article from The New York Times on the demographic changes that will give rise to a whole new world in terms of population distribution. Some skepticism about the effects of Donamebad on the evolution of Alzheimer’s.

When it comes to Global Health, The Economist looks at why the malaria vaccine has taken so long to develop. This is apparently due to cycle changes of the Plasmodium parasite. Singapore is a world leader in the marketing of cultured meat, which is possibly called to change many things in our eating habits.

Regarding International Health Policy, the WHO in its weekly covid monitoring newsletter on covid warns that, although the number of new cases and mortality are falling, this disease continues to be a threat, which requires maintenance of surveillance systems and periodic reports. The National Health Service, despite its deep crisis, continues to be a benchmark in terms of reflections on health and health systems. This time the King’s Fund is publishing a report on the kind of participatory leadership needed in the healthcare system.

If we talk about National Health Policy (Spain), we want to highlight the interesting book “Conversations for better health”, which consists of deep and nuanced reflections on many topics, carried out by two consolidated values in Spanish healthcare arena (Jesús María Fernández Díaz and José Martínez Olmos): the importance of Public Health, the need for the Public Health Agency, the opacity of our system in terms of information on results and quality, financing, co-payment, the challenges of Primary Care, the necessary new care model, the contributions of digital health, etc. When improvisations and light comments abound, often made from advertising or simple communication, this conversation between two experienced experts, who treasure experience and knowledge, is a must read. It can be purchased on Amazon.

In the field of Companies, internationally, there are two great opportunities for the pharmaceutical industry, one in the short term, such as all medications against obesity and Alzheimer’s, and another in the longer term, such as anti-aging therapies.

Biomedicine

Global Health

International Health Policy

National health policy

Companies

 

 

7 days in healthcare (June 12th-18th, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, to point out that human embryos have been produced without eggs or sperm, using stem cells, which raises far-reaching ethical questions. Joseph Alpert, editor of the American Journal of Medicine, recounts the 10 advances in clinical medicine he has seen since he was an intern in 1969-70. A whole different world, from the mortality of myocardial infarction, the evolution of HIV, the approach to leukemia, the possibilities offered by ICUs, the treatment of tuberculosis, etc. From that point of view, there is no doubt that the world is better than fifty years ago.

As regards Global Health, an unexplained increase in the incidence of cancer has been detected in people under 50 years of age, with this trend particularly affecting the population between 25-29 years of age. The Lancet denounces what it considers pressure from the pharmaceutical industry in the pandemic treaty, currently under discussion at the initiative of the WHO, according to a draft that was leaked on May 22 and published. It would be good if this treaty corrected the major failures that occurred during the covid pandemic in access to vaccines in developing countries, particularly in Africa.

Regarding International Health Policy, according to the weekly WHO report, covid is declining in both the number of cases and deaths in all regions of the world. Forecasts of health spending in the USA are published. Although growth will be moderate in the coming years, it will reach 20% of GDP in 2023, more than any country in the world. The National Oncology Plan in Italy is published. The European Monitoring Center for Drugs publishes its report for 2023. Cannabis, followed by cocaine, are the most widely used illegal drugs in Europe.

If we talk about National Health Policy (Spain), the incidence of covid is decreasing, which makes the government consider removing the mandatory use of masks in pharmacies and health centers. Madrid, the autonomous community with the shortest waiting list for non-urgent surgery. Although our country has a low birth rate, the use of in vitro fertilization is skyrocketing.

At the Business level, internationally, Philips has serious problems with faulty respirators. A collective accuses this company of involuntary manslaughter. The 10 largest pharmaceutical companies have more than 110,000 million dollars available for operations to purchase other companies, a move that is undoubtedly spurred on by the loss of patents in many of them. Lobbyists linked to tobacco companies are accused of advertising vaping online, against the recommendations of the WHO, with many reservations about this practice, considering it harmful to health. On a national level, Quirón presents its new hospital project in Badalona. Grifols will refinance its debt after divesting from its business in China. Asterion, the largest Spanish fund, breaks into health, by buying a health transport company.

Biomedicine

Global Health

International Health Policy

  • Europe
    • The European Monitoring Center for Drugs publishes the report on Drugs 2023: Trends and development. Cannabis (marijuana or hashish) is the most widely used illicit drug in Europe, followed by cocaine. Heroin is the most widely used opioid and the one that causes the most health problems (https://www.emcdda.europa.eu/publications/european-drug-report/2023_en)

National Health Policy

Companies

7 days in healthcare (May 1st-7th, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, to point out the interest in certain therapies using viruses that engulf bacteria to address infections caused by antibiotic-resistant bacteria. Progress continues to be made in breaking the blood-brain barrier, which will make it possible to better treat certain brain tumors, which until now have not been reached by medication.

As regards Global Health, the WHO declares the end of the emergency due to the covid pandemic, although not the covid, which is still with us. Since its inception this disease has caused more than 20 million deaths globally. Gavi reveals his plans for a malaria vaccine, another major global plague.

As for International Health Policy, he has highlighted the rise in the price of tobacco in France (a good measure against smoking), and Australia wants to limit the use of electronic cigarettes. The ECDC brings out an interesting report with the lessons of the pandemic: “More investment, improvement of surveillance systems, improvement of risk communication, community participation and greater participation between countries” could be the summary.

If we talk about National Health Policy (Spain), in the update of the Stability Program 2023-2026, the % of GDP dedicated to public healthcare spending does not change, remaining at 6.9%. It is evident that only increasing spending does not solve the problems of our health system, but it is difficult to see how they can be solved without increasing spending, as the government proposes. The Spanish Association against Cancer, through the mouth of its president, denounces that Spain has the cheapest tobacco in Europe: “the tobacconist of Europe” calls for this situation. Interesting article by Juan Abarca Cidón, who presents a decalogue to avoid the collapse of our health system. The measurements are very clear and direct. It will be possible to qualify or even disagree with some, but there is no doubt that the problems are addressed. Not like the framework programs of the majority parties for the 28-M elections, which seem to try not to raise any suspicion, by saying nothing.

At the Corporate level, at the international level, Lilly presents a new drug that slows down the progression of Alzheimer’s. The birth of a large market linked to Artificial Intelligence in health is in sight, according to the report by Siemens Financial Services. As far as our country is concerned, Cofares reaches a sales record in 2022. Grifols enters the field of leukemia.

Biomedicine

Global Health

International Health Policy

National health policy

  • Interesting article with a decalogue of reforms in our health system
    • Article by Juan Abarca Cidón, the proposals range from a political agreement; increase general spending on health; finalist financing with certain objectives; reduce costs, considering the co-payment; new governance model at all levels; new care organization model with a greater role for nursing; deal with patient problems, such as waiting lists; address the problems of professionals; normalize the activity of the private sector; and promote the Public Health Agency (https://www.elespanol.com/edicion/20230430/decalogo-reformas-evitar-colapso-sanidad/760293970_12.html)

Companies

 

 

7 days in healthcare (February 27th-March 5th, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, The Economist celebrates medicines against obesity as a great revolution, at a particularly opportune moment, since the WHO is continually warning of the global epidemic of this disease. Psychedelics appear to be making their way into treatments for mental illness. The WHO is working on a new vaccine against bird flu, fearing that this virus will “jump” to humans, which already seems to have occurred in Asia.

With regard to Global Health, the change of management in two entities such as the World Bank and Gavi, very promising. In this last body, for the first time, the representative of a country receiving aid (Nigeria) occupies the maximum responsibility. Solutions are sought for the global shortage of certain medicines. There may be many causes, but it seems that the concentration of production in the geographic area of India and China may be at the root of the logistical problems.

As for International Health Policy, in the United States the battle for abortion, after the ruling of the American Supreme Court, is even transferred to abortion pills, which are trying to be banned in certain states. In the United Kingdom, pharmaceutical companies ask the Government for a tax cut, something that the Government does not seem willing to grant. In Canada, certain establishments are authorized to sell cocaine, in an attempt, we’ll see if it’s effective, to curb overdose problems. Two new clinics for LGBT patients open in Tel-Aviv.

If we talk about National Health Policy (Spain), in terms of covid, the accumulated incidence continues to rise slightly, with a fairly high mortality (around 100 patients a week). The medical conflict continues in several autonomous communities, but with special virulence in Madrid, where there is even a possible strike by hospital doctors, which would be a very important qualitative change. A group of Catalan healthcare workers resorts to the Government’s call to demand Catalan to be able to run for office, where had that bilingualism left off? The Amancio Ortega Foundation donates 30 million for the construction of the first pediatric palliative care center, which will be open to children from all Spanish communities. Despite how hard it is, there are children who are going to die and who are known to die. Those are the recipients of that center. Extremadura reaches an agreement with BIOSIM to promote biosimilars through profit-sharing programs. The wide diffusion of generics and biosimilars, critical for the permanent incorporation of innovation. Great presence at the Barcelona Mobile Fair of health technology, mainly surgical robots and telemedicine solutions.

In the field of companies, at the international level, BioNTech will open a center of excellence in mRNA technology in Israel. In Spain, Grifols takes full control of the biotech company Access Biologicals.

Biomedicine

Global Health

International Health Policy

  • COVID

National health policy

Companies

7 days in healthcare (February 13th-19th, 2023)

/in /by

 

 

Summary

From the point of view of Biomedicine, it is worth highlighting the reference in the British Medical Journal on the questionable value of colorectal cancer screening, according to a double-blind study of the results of colonoscopy, with a large population followed up, without detecting reductions in the mortality from this type of cancer. The first vaccine against the syncytial virus, responsible for many deaths, both newborns and adults, is presented. The results of a test that detects prostate cancer with great precision, with a simple blood test, are published.

With regard to Global Health, the New England Journal Medicine published an article on the correct path to eradicate polio, which is once again a problem in many countries, defending universal immunization against polio, in instead of virus eradication strategies. The Lancet reviews the One Health strategy, this approach that links climate change, animal health and human health as something that cannot be addressed separately. It is detected that poor countries desperately need access to cheap generics, since in these countries, due to less competition between manufacturers, generics are more expensive than in developed countries. Malaria is spreading across Africa as climate change allows the geographic spread of the mosquitoes that transmit it.

Regarding International Health Policy, there is a great debate in the United States about the future of Social Security and Medicare, with very opposed positions between Democrats and Republicans. In the UK, the number of people waiting more than 18 weeks for treatment exceeds three million in England alone. In France, the very open debate on euthanasia continues with wide participation, with the involvement of President Macron himself. In Chile, the crisis in the private health sector threatens the entire Chilean health system. The collapse of the Isapres (Chilean health insurers) would mean that 3.2 million people would pass into the already congested public Fonasa system. Poland bans energy drinks for those under 18, a move welcomed by doctors in that country. The European Commission finalizes the European pharmaceutical strategy, with new approaches towards generics and orphan drugs. The EFPIA, the European employers’ association for pharmaceutical companies, criticizes what is becoming known about this reform, considering it harmful to competitiveness.

If we talk about National Health Policy (Spain), the cumulative incidence of covid continues to rise slightly. From a regulatory point of view, two important laws are approved: the so-called “trans law” and the new abortion law. From various sectors of the healthcare industry, objections had been made to certain elements of both laws, the consequences of which will have to be expected. As far as the medical conflict is concerned, it is increasingly clear that the conflict in Madrid is one thing and another in the other communities. Although the problems of Primary Care are national, and therefore the national government cannot inhibit itself as it is doing, what is specific to Madrid is the way in which the Community government approaches it, which simply attributes it to a “conspiracy of the left”, which contributes to its exacerbation, prolongation and expansion (it is also announces conflict among hospital doctors). Both the international press (Financial Times, Le Monde) and the national one (Zarzalejos in El Confidencial and others) strongly criticize this approach by the Community of Madrid, which has published a decalogue of excellence in Madrid’s healthcare, strongly criticized for its inaccuracies. In other communities, on the other hand, with all the difficulties, agreements are being reached. The national government also uses this conflict to enter into health, trying to neutralize criticism of the “yes is yes” law. Those who want politics out of healthcare don’t know what they’re saying. On the contrary, we need a political debate on high altitude and adult health. Just the opposite of what is happening. Private insurance policies are rising in price, something that the sector had been demanding for years.

At the Corporate level, at the international level, it is proposed that health information (largely from the NHS) be the basis of a British sovereign wealth fund, in the same way that a Norwegian sovereign wealth fund is based on information about oil. Grifols announces a savings plan that includes 2,300 layoffs, which has been highly received by the Stock Market, significantly raising the shares of this company.

Biomedicine

Global Health

International Health Policy

  • Chili
    • The crisis in the private sector threatens the entire Chilean health system. A 2010 court ruling prevents adjusting policies by age and sex. Although the measure had not been implemented, it seems that the government wants to do so. The collapse of the Isapres (health insurers in Chile) would mean that 3.2 million people would pass into the already congested public Fonasa system (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00321-5/fulltext)

National health policy

Companies

7 days in healthcare (December 12th-18th, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, The Lancet commemorates the 200th anniversary of the birth of Pasteur, the creator of the germ theory. Even today a high percentage of deaths are from infections. Promising results of an mRNA vaccine against melanoma, presented by Moderna and Merck.

As far as Global Health is concerned, it is worth highlighting the article published in Nature that says that without a strategy and global financing of vaccines, the world will be unable to successfully face new epidemics.

As for international health policy, the discouraging news of China’s abandonment of the covid-zero policy continues, when the country is not prepared and is most likely to suffer high mortality. The CDC quantifies the deaths from persistent covid in the USA. The conflict of nurses in the NHS continues, which coincides with the appearance of a report from the Institute for Fiscal Studies in the United Kingdom that attributes the problems of the NHS to underfunding of the system. New Zealand, the second country in the world to announce a ban on tobacco sales.

If we talk about national health policy (Spain), in terms of covid, the incidence continues to decrease, what has not completely decreased, or has decreased very slowly, is mortality (236 deaths in the last week). After confinement in a unit of the Regional Ministry of Health, the strike committee of primary care doctors in Madrid decided to continue the strike, extending the conflict to a demonstration, along the lines of the “white tides”.

In the field of companies, internationally, it seems that Jeff Bezos and Bill Gates are making an important bet in the field of neurotechnology with the company Synchron. As far as national news is concerned, perhaps highlighting that it seems that the hopes placed on the Spanish HIPRA vaccine are fading.

Biomedicine

Global Health

International Health Policy

National health policy

Companies